Somayeh Najafi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Somayeh Najafi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Roya Sherkat
Immunodeficiency Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 shared publications Sedigheh Asgary
Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 shared publications- Alireza Emami Naeini
Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
1 shared publication - Alireza Ghannadi
Department of Pharmacognosy and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
1 shared publication Alireza Helalat
PhD, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
1 shared publication- Amirhossein Sahebkar
Mashhad University of Medical Sciences
1 shared publication
Latest Publications
- Open Access
- 2 October 2026
- Published by Springer Nature in Clinical and Experimental Medicine
Immunodeficiency following rituximab therapy: clinical spectrum and monitoring strategies
- 2 October 2026
- Published by Springer Nature in Clinical and Experimental Medicine
Open AccessImmunodeficiency following rituximab therapy: clinical spectrum and monitoring strategies
- Open Access
- 1 January 2018
- Published by Wolters Kluwer Health in Advanced Biomedical Research
- Vol. 7 (1) , 45
Establishment and Development of the First Biobank of Inflammatory Bowel Disease, Suspected to Primary Immunodeficiency Diseases in Iran
Background: Inflammatory bowel disease (IBD) might be an immunodeficiency rather than an excessive inflammatory reaction. IBD, suspected to primary immunodeficiency diseases biobank (IBDSPIDB) as a resource for researches can help improve the prevention, diagnosis, and illness treatment and the health promotion throughout the society. Therefore, we launched the biobank of IBDSPID for the first time in Iran. Materials and Methods: This study was designed to provide the IBDSPIDB to have a high-quality DNA, RNA, and cDNA. Among of 365 patients, 39 have inclusion criteria that were as below: (1) IBD diagnosis before 5 years of age. (2) Resistance to conventional therapy of IBD. (3) Severe IBD. (4) Signs of SPID (including ear infections or pneumonia or recurrent sinus within the 1-year period; failure to thrive; poor response to the prolonged use of antibiotics; persistent thrush or skin abscesses; or a family history of PID). Results: Out of 39 patients, 51.3% were males. The mean age was 32.92 ± 15.90 years old. Ulcerative colitis (79.5%) was more than Crohn's disease. The majority of patients (50.0%) had severe IBDSPID. Resistance to drugs and consanguinity was 12.9% and 47.4%, respectively. Age at onset in 65.8% of patients was after 17 years old. Patients with autoimmune, allergy, and immunodeficiency disease history were 33.3%, 33.3%, and 10.36%, respectively. RNA and cDNA yields large quantities of high-quality DNA obtained and stored. Conclusion: Our biobank would be valuable for future genetic and molecular study to be more about the relation between IBD and PID.
- 1 January 2018
- Published by Wolters Kluwer Health in Advanced Biomedical Research
- Vol. 7 (1) , 45
Open AccessEstablishment and Development of the First Biobank of Inflammatory Bowel Disease, Suspected to Primary Immunodeficiency Diseases in Iran
Background: Inflammatory bowel disease (IBD) might be an immunodeficiency rather than an excessive inflammatory reaction. IBD, suspected to primary immunodeficiency diseases biobank (IBDSPIDB) as a resource for researches can help improve the prevention, diagnosis, and illness treatment and the health promotion throughout the society. Therefore, we launched the biobank of IBDSPID for the first time in Iran. Materials and Methods: This study was designed to provide the IBDSPIDB to have a high-quality DNA, RNA, and cDNA. Among of 365 patients, 39 have inclusion criteria that were as below: (1) IBD diagnosis before 5 years of age. (2) Resistance to conventional therapy of IBD. (3) Severe IBD. (4) Signs of SPID (including ear infections or pneumonia or recurrent sinus within the 1-year period; failure to thrive; poor response to the prolonged use of antibiotics; persistent thrush or skin abscesses; or a family history of PID). Results: Out of 39 patients, 51.3% were males. The mean age was 32.92 ± 15.90 years old. Ulcerative colitis (79.5%) was more than Crohn's disease. The majority of patients (50.0%) had severe IBDSPID. Resistance to drugs and consanguinity was 12.9% and 47.4%, respectively. Age at onset in 65.8% of patients was after 17 years old. Patients with autoimmune, allergy, and immunodeficiency disease history were 33.3%, 33.3%, and 10.36%, respectively. RNA and cDNA yields large quantities of high-quality DNA obtained and stored. Conclusion: Our biobank would be valuable for future genetic and molecular study to be more about the relation between IBD and PID.
- Open Access
- 2 December 2016
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 12 (1) , 1-11
Gene mutations responsible for primary immunodeficiency disorders: A report from the first primary immunodeficiency biobank in Iran
Primary immunodeficiency (PID) is a heterogeneous group of inheritable genetic disorders with increased susceptibility to infections, autoimmunity, uncontrolled inflammation and malignancy. Timely precise diagnosis of these patients is very essential since they may not be able to live with their congenital immunity defects; otherwise, they could survive with appropriate treatment. DNA biobanks of such patients could be used for molecular and genetic testing, facilitating the detection of underlying mutations in known genes as well as the discovery of novel genes and pathways. According to the last update of the International Union of Immunological Societies (IUIS) classification, patients are registered in our biobank during a period of 15 years. All patients’ data were collected via questionnaire and their blood samples were taken in order to extract and protect their DNA content. Our study comprised 197 patients diagnosed with PID. Antibody deficiency in 50 patients (25.4%), phagocytic defect in 47 patients (23.8%) and combined immunodeficiency with associated/syndromic feature in 19 patients (9.6%) were the most common PID diagnoses, respectively. The most common variant of PID in our study is common variable immunodeficiency, which accounted for 20 cases (10.1%), followed by chronic mucocutaneous candidiasis in 15 patients (7.9%) and congenital neutropenia in 13 patients (7%). Mean age at onset of disease was 4 years and mean age of diagnosis was 9.6 years. The average diagnostic delay was 5.5 years, with a range of 6 months to 46 years. Parental consanguinity and history of PID in family were observed in 70.2 and 48.9% of the patients, respectively. The majority of PID patients (93.3%) were from families with low socioeconomic status. This prospective study was designed to establish a PID Biobank in order to have a high quality DNA reservoir of these patients, shareable for international diagnostic and therapeutic collaborations. This article emphasizes the need to raise the awareness of society and general practitioners to achieve timely diagnosis of these patients and prevent current mismanagements.
- 2 December 2016
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 12 (1) , 1-11
Open AccessGene mutations responsible for primary immunodeficiency disorders: A report from the first primary immunodeficiency biobank in Iran
Primary immunodeficiency (PID) is a heterogeneous group of inheritable genetic disorders with increased susceptibility to infections, autoimmunity, uncontrolled inflammation and malignancy. Timely precise diagnosis of these patients is very essential since they may not be able to live with their congenital immunity defects; otherwise, they could survive with appropriate treatment. DNA biobanks of such patients could be used for molecular and genetic testing, facilitating the detection of underlying mutations in known genes as well as the discovery of novel genes and pathways. According to the last update of the International Union of Immunological Societies (IUIS) classification, patients are registered in our biobank during a period of 15 years. All patients’ data were collected via questionnaire and their blood samples were taken in order to extract and protect their DNA content. Our study comprised 197 patients diagnosed with PID. Antibody deficiency in 50 patients (25.4%), phagocytic defect in 47 patients (23.8%) and combined immunodeficiency with associated/syndromic feature in 19 patients (9.6%) were the most common PID diagnoses, respectively. The most common variant of PID in our study is common variable immunodeficiency, which accounted for 20 cases (10.1%), followed by chronic mucocutaneous candidiasis in 15 patients (7.9%) and congenital neutropenia in 13 patients (7%). Mean age at onset of disease was 4 years and mean age of diagnosis was 9.6 years. The average diagnostic delay was 5.5 years, with a range of 6 months to 46 years. Parental consanguinity and history of PID in family were observed in 70.2 and 48.9% of the patients, respectively. The majority of PID patients (93.3%) were from families with low socioeconomic status. This prospective study was designed to establish a PID Biobank in order to have a high quality DNA reservoir of these patients, shareable for international diagnostic and therapeutic collaborations. This article emphasizes the need to raise the awareness of society and general practitioners to achieve timely diagnosis of these patients and prevent current mismanagements.
- Open Access
- 1 January 2013
- Published by Wiley in The Scientific World Journal
- Vol. 2013 (1) , 365892
Antihyperlipidemic Effects of Sesamum indicum L. in Rabbits Fed a High‐Fat Diet
The present study aimed to investigate the anti‐hyperlipidemic effects of sesame in a high‐fat fed rabbit model. Animals were randomly divided into four groups of eight animals each for 60 days as follows: normal diet, hypercholesterolemic diet (1% cholesterol), hypercholesterolemic diet (1% cholesterol) + sesame seed (10%), and hypercholesterolemic diet (1% cholesterol) + sesame oil (5%). Serum concentrations of total cholesterol, LDL‐C, HDL‐C, triglycerides, apoA and apoB, SGOT, SGPT, glucose and insulin were measured at the end of supplementation period in all studied groups. Hypercholesterolemic feeding resulted in a significant elevation of TC, TG, LDL‐C, HDL‐C, SGOT and SGPT as compared to the normocholesterolemic diet group (P < 0.05). Supplementation with sesame seed did not cause any significant alteration in lipid profile parameters, apolipoproteins, hepatic transaminases, glucose and insulin as compared to the hypercholesterolemic diet group (P > 0.05). In contrast, rabbits supplemented with sesame oil were found to have lower circulating concentrations of TC, LDL‐C, HDL‐C, SGOT and SGPT (P < 0.05), whilst concentrations of TG, apoA, apoB, insulin and glucose remained unaltered compared to the hypercholesterolemic diet group (P > 0.05). Supplementation with sesame oil, but not sesame seed, can ameliorate serum levels of lipids and hepatic enzymes in rabbits under a high‐fat diet.
- 1 January 2013
- Published by Wiley in The Scientific World Journal
- Vol. 2013 (1) , 365892
Open AccessAntihyperlipidemic Effects of Sesamum indicum L. in Rabbits Fed a High‐Fat Diet
The present study aimed to investigate the anti‐hyperlipidemic effects of sesame in a high‐fat fed rabbit model. Animals were randomly divided into four groups of eight animals each for 60 days as follows: normal diet, hypercholesterolemic diet (1% cholesterol), hypercholesterolemic diet (1% cholesterol) + sesame seed (10%), and hypercholesterolemic diet (1% cholesterol) + sesame oil (5%). Serum concentrations of total cholesterol, LDL‐C, HDL‐C, triglycerides, apoA and apoB, SGOT, SGPT, glucose and insulin were measured at the end of supplementation period in all studied groups. Hypercholesterolemic feeding resulted in a significant elevation of TC, TG, LDL‐C, HDL‐C, SGOT and SGPT as compared to the normocholesterolemic diet group (P < 0.05). Supplementation with sesame seed did not cause any significant alteration in lipid profile parameters, apolipoproteins, hepatic transaminases, glucose and insulin as compared to the hypercholesterolemic diet group (P > 0.05). In contrast, rabbits supplemented with sesame oil were found to have lower circulating concentrations of TC, LDL‐C, HDL‐C, SGOT and SGPT (P < 0.05), whilst concentrations of TG, apoA, apoB, insulin and glucose remained unaltered compared to the hypercholesterolemic diet group (P > 0.05). Supplementation with sesame oil, but not sesame seed, can ameliorate serum levels of lipids and hepatic enzymes in rabbits under a high‐fat diet.
- Open Access
- 1 January 2012
- Vol. 7 (4) , 146-150
Efficiency of black cumin seeds on hematological factors in normal and hypercholesterolemic rabbits
Hypercholesterolemia is among the most common health problems treated with traditional remedies. Nigella sativa (NS) is an effective plant for treating hypercholesterolemia. However, the effects of this herb on hematologic factors and hemostasis system have not been elucidated. This study was designed to investigate the effects of NS on these factors in both normal and hypercholesterolemic rabbits. In this research, twenty rabbits were randomly distributed into four groups of five. The groups received four different diets, namely normal, normal + NS (5%), hypercholesterolemic (1% cholesterol), and hypercholesterolemic (1% cholesterol) + NS (5%), for 8 weeks. After this period, WBC (white blood cell), RBC (red blood cell), HTC (hematocrit), HGB (hemoglobin content), PLT (platelet), fibrinogen (FIB) and factors VII (F VII) were measured. Using NS significantly increased PLT count in the normal group. In addition, it significantly decreased WBC counts in the hypercholesterolemic group (P < 0.05). However, dietary use of NS did not have any effects on other hematologic factors including RBC, HTC, HGB, FIB, and F VII (P < 0.05). Increased PLT numbers might cause enhanced coagulation. The achieved results call for more research on the effects of various diets (hypercholesterolemic and normal diet) supplemented with NS on different coagulation factors and hemostasis system.
- 1 January 2012
- Vol. 7 (4) , 146-150
Open AccessEfficiency of black cumin seeds on hematological factors in normal and hypercholesterolemic rabbits
Hypercholesterolemia is among the most common health problems treated with traditional remedies. Nigella sativa (NS) is an effective plant for treating hypercholesterolemia. However, the effects of this herb on hematologic factors and hemostasis system have not been elucidated. This study was designed to investigate the effects of NS on these factors in both normal and hypercholesterolemic rabbits. In this research, twenty rabbits were randomly distributed into four groups of five. The groups received four different diets, namely normal, normal + NS (5%), hypercholesterolemic (1% cholesterol), and hypercholesterolemic (1% cholesterol) + NS (5%), for 8 weeks. After this period, WBC (white blood cell), RBC (red blood cell), HTC (hematocrit), HGB (hemoglobin content), PLT (platelet), fibrinogen (FIB) and factors VII (F VII) were measured. Using NS significantly increased PLT count in the normal group. In addition, it significantly decreased WBC counts in the hypercholesterolemic group (P < 0.05). However, dietary use of NS did not have any effects on other hematologic factors including RBC, HTC, HGB, FIB, and F VII (P < 0.05). Increased PLT numbers might cause enhanced coagulation. The achieved results call for more research on the effects of various diets (hypercholesterolemic and normal diet) supplemented with NS on different coagulation factors and hemostasis system.